Biomarker Testing Global Market Report 2025

The biomarker testing market size has grown rapidly in recent years. It will grow from $17.51 billion in 2024 to $19.75 billion in 2025 at a compound annual growth rate (CAGR) of 12.8%. The growth during the historic period can be attributed to the rising adoption of personalized medicine, the increased utilization of biomarkers in oncology, the growing prevalence of chronic illnesses, expanded research funding in the life sciences sector, and the heightened demand for early disease detection.

The biomarker testing market size is expected to see rapid growth in the next few years. It will grow to $31.63 billion in 2029 at a compound annual growth rate (CAGR) of 12.5%. The growth in the forecast period can be attributed to the expanding application of biomarkers in non-oncology conditions, increasing investments in companion diagnostics, greater integration of artificial intelligence into diagnostic processes, the rising adoption of point-of-care testing, and growing awareness of preventive healthcare. Key trends expected during the forecast period include advancements in sequencing technologies, ongoing innovations in liquid biopsy, progress in multiplex biomarker platforms, breakthroughs in proteomics and metabolomics, and rising investments in research and development.

The rising cancer burden is expected to drive the growth of the biomarker testing market in the coming years. Cancer comprises a group of diseases marked by the uncontrolled growth and spread of abnormal cells. This increasing burden is largely attributed to lifestyle-related risk factors such as unhealthy diets, smoking, physical inactivity, and excessive alcohol consumption. Biomarker testing plays a vital role in cancer detection by enabling early and accurate identification of disease-specific markers, thereby improving diagnostic precision. It also facilitates personalized treatment strategies, resulting in improved patient outcomes and more efficient healthcare management. For instance, in July 2024, the Australian Institute of Health and Welfare reported that 160,570 cancer cases were diagnosed in Australia in 2022, an increase of 3,789 cases from 156,781 in 2021. Therefore, the growing incidence of cancer is contributing significantly to the expansion of the biomarker testing market.

Major companies operating in the biomarker testing market are focusing on developing technologically advanced solutions, such as immunohistochemistry (IHC) technology, to enhance diagnostic accuracy, enable early disease detection, and support personalized treatment strategies. Immunohistochemistry (IHC) is a laboratory technique that utilizes antibodies to detect specific proteins in tissue samples, enabling the identification and visualization of biomarkers critical for disease diagnosis and research. For example, in July 2023, Quest Diagnostics Incorporated, a U.S.-based medical laboratory company, launched a new tissue-based prostate cancer biomarker test through its AmeriPath business. This test leverages proprietary biomarkers EV1, EV2, and EV3 to improve diagnostic precision by helping physicians more accurately identify and distinguish aggressive prostate cancer types. It addresses a critical clinical need by enhancing grading consistency and guiding appropriate, individualized treatment strategies.

In August 2025, Quanterix Corp., a U.S.-based life sciences company, acquired Emission Inc. for approximately $70 million. This acquisition is aimed at expanding Quanterix’s technology portfolio and market presence by incorporating Emission’s advanced multiplex and multi-omic assay technologies. The integration is expected to strengthen Quanterix’s position in the biomarker testing sector, enhance its diagnostic capabilities, and open new market opportunities. Emission Inc. is a U.S.-based biotechnology company specializing in multiplex and multi-omic assay solutions for biomarker testing.

Major players in the biomarker testing market are Roche Diagnostics International Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Merck KGaA, Siemens Healthineers AG, Becton Dickinson and Company, GE HealthCare Technologies Inc., Agilent Technologies Inc., Illumina Inc., Hologic Inc., Charles River Laboratories International Inc., PerkinElmer Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., DiaSorin S.p.A., Myriad Genetics Inc., Guardant Health Inc., Sino Biological Inc., Proteome Sciences plc.

North America was the largest region in the biomarker testing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in biomarker testing report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the biomarker testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Biomarker testing involves examining blood, tissue, or other bodily fluids to detect specific biological indicators that signify either normal or pathological conditions. This process is vital for disease diagnosis, monitoring disease progression, and creating personalized treatment strategies.

Biomarker testing includes several product types such as consumables, instruments, services, and more. Consumables refer to items that are used and depleted during procedures and must be replenished regularly, including medical supplies, food items, or office essentials. The primary technologies employed are polymerase chain reaction (PCR), next-generation sequencing (NGS), immunoassays, among others. It is widely used in fields such as oncology, cardiology, neurology, and infectious diseases, with key end-users including hospitals, diagnostic labs, research institutions, and other healthcare settings.

The biomarker testing market research report is one of a series of new reports that provides biomarker testing market statistics, including the biomarker testing industry global market size, regional shares, competitors with the biomarker testing market share, detailed biomarker testing market segments, market trends, and opportunities, and any further data you may need to thrive in the biomarker testing industry. These biomarker testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The biomarker testing market consists of revenues earned by entities by providing services such as clinical biomarker testing services, bioinformatics and data analysis services, sample collection and biobanking services, and companion diagnostic services. The market value includes the value of related goods sold by the service provider or included within the service offering. The biomarker testing market includes sales of analytical instruments, imaging devices, lab-on-a-chip and microfluidic devices, and data acquisition and integration hardware. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values generated by organizations in the specified geography within the market, irrespective of where they are produced. They do not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.